移动应用评估患者报告结局对医患互动的影响
在瑞士风湿病临床质量管理登记注册的患者中,观察使用移动应用(iDialog和COmPASS)记录患者报告结局(PROs)对医患互动的影响。分析2111例患者(1799例非应用用户、150例仅用应用、162例用应用并讨论数据),结果显示用应用并讨论数据的患者对共享决策和医生察觉病情波动的评价更高,而仅用应用不讨论的患者无此改善。
要点
- 使用应用并与医生讨论数据与更高的共享决策评分相关(OR 1.7)。
- 使用应用并与医生讨论数据与医生察觉病情波动评分更高相关(OR 2.0)。
- 仅使用应用而不讨论数据者,医患互动改善不明显。
核心结论
- 使用应用记录PROs并与风湿科医生讨论数据的患者,对医患互动的评价优于仅用应用不讨论者及非应用用户。
- 若未将应用数据整合到诊疗流程中,PROs应用对医患互动的贡献可能有限。
研究设计与样本
- 观察性研究,基于瑞士风湿病临床质量管理登记注册,提供移动应用(iDialog和COmPASS)供患者在就诊间期使用经验证的患者报告结局(PROs)追踪病情。
- 共分析2111例患者:1799例非应用用户、150例仅用应用用户、162例用应用并讨论数据用户;其中男性43%,类风湿关节炎902例、中轴型脊柱关节炎766例、银屑病关节炎443例。
主要发现
- 应用用户比非应用用户年轻(平均年龄47岁 vs 51岁,p<0.001)。
- 与非应用用户相比,用应用并讨论数据组对风湿科医生的共享决策评分更高(OR 1.7,95% CI 1.1至2.4)。
- 与非应用用户相比,用应用并讨论数据组对医生察觉病情波动的评分更高(OR 2.0,95% CI 1.3至3.1)。
- 仅用应用组未见上述改善。
关键数值与推荐
- 共享决策评分:用应用并讨论数据组 vs 非应用用户,OR 1.7(95% CI 1.1至2.4)。
- 医生察觉病情波动评分:用应用并讨论数据组 vs 非应用用户,OR 2.0(95% CI 1.3至3.1)。
- 年龄比较:应用用户平均47岁 vs 非应用用户51岁,p<0.001。
临床怎么用
- 在风湿病随访中,鼓励患者使用移动应用记录PROs,并确保这些数据在就诊时被医生查看和讨论。
- 仅提供应用而不整合数据到诊疗流程,可能不足以改善医患互动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the effect of apps measuring patient-reported outcomes (PROs) on patient-provider interaction in the rheumatic diseases in an observational setting. METHODS: Patients in the Swiss Clinical Quality Management in Rheumatic Diseases Registry were offered mobile apps (iDialog and COmPASS) to track disease status between rheumatology visits using validated PROs (Rheumatoid Arthritis Disease Activity Index-5 score, Bath Ankylosing Spondylitis Disease Activity Index score, Routine Assessment of Patient Index Data-3 score and Visual Analogue Scale score for pain, disease activity and skin symptoms). We assessed two aspects of patient-provider interaction: shared decision making (SDM) and physician awareness of disease fluctuations. We used logistic regressions to compare outcomes among patients who (1) used an app and discussed app data with their physician (app+discussion group), (2) used an app without discussing the data (app-only group) or (3) did not use any app (non-app users). RESULTS: 2111 patients were analysed, including 1799 non-app users, 150 app-only users and 162 app+discussion users (43% male; with 902 patients with rheumatoid arthritis, 766 patients with axial spondyloarthritis and 443 patients with psoriatic arthritis). App users were younger than non-app users (mean age of 47 vs 51 years, p<0.001). Compared with non-app users, the app+discussion group rated their rheumatologist more highly in SDM (OR 1.7, 95% CI 1.1 to 2.4) and physician awareness of disease fluctuations (OR 2.0, 95% CI 1.3 to 3.1). This improvement was absent in the app-only group. CONCLUSION: App users who discussed app data with their rheumatologist reported more favourably on patient-provider interactions than app users who did not and non-app users. Apps measuring PROs may contribute little to patient-provider interactions without integration of app data into care processes.
引用
- Shaw Y, Courvoisier DS, Scherer A, et al. Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction. RMD Open. 2021. PMID: 33811177. doi:10.1136/rmdopen-2021-001566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。